Bambusa Therapeutics, Inc.

• S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue

  Filed Oct 26

  Develops dual-target antibodies led by eczema candidate BBT001; IPO targets $135M net at midpoint to advance clinical trials

No filings match these filters. Show all 8-K events

Request longer coverage